Table1.
Characteristics of the Study Group (n=90)
| No. (%) on Inotuzumab Schedule | ||||
|---|---|---|---|---|
| Characteristic | Category | Single-dose (n=49) | Weekly (n=41) | Overall (n=90) |
| Age (yrs) | ≤ 18 | 3 (6) | 3 (7) | 6 (7) |
| ≥ 60 | 12 (24) | 13 (32) | 25 (28) | |
| PS (ECOG) | 0-1 | 44 (90) | 37 (90) | 81 (90) |
| ≥ 2 | 5 (10) | 4 (10) | 9 (10) | |
| Salvage status | S1 | 13 (27) | 16 (39) | 29 (32) |
| S1, CRD1 < 12 mos | 3 (6) | 12 (29) | 15 1(7) | |
| S1, CRD1 ≥ 12 mos | 7 (14) | 2 (5) | 9 (10) | |
| S2 | 24 (49) | 10 (24) | 34 (38) | |
| ≥ S3 | 12 (24) | 15 (37) | 27 (30) | |
| Prior HCVAD regimen | Yes | 28 (57) | 29 (71) | 57 (63) |
| Karyotype | Diploid | 12 (24) | 9 (22) | 21 (23) |
| Ph-positive | 7 (14) | 8 (20) | 15 (17) | |
| T (4;11) | 5 (10) | 3 (7) | 8 (9) | |
| Other | 25 (51) | 21 (51) | 46 (51) | |
| Prior allo SCT | Yes | 7 (14) | 3 (7) | 10 (11) |
| % CD22-positive | > 90 | 28 (57) | 31 (76) | 59 (66) |
| 70-89 | 14 (29) | 8 (20) | 22 (24) | |
| 50-69 | 7 (14) | 2 (5) | 9 (10) | |
• Patients on weekly inotuzumab were more frequently in Salvage 1 with CRD1 < 12 months (p=.003) while patients on single-dose inotuzumab were more frequently in Salvage 2 (p=.016). No other significant differences were evident in the 2 study group characteristics.